<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref61">
 <mixed-citation publication-type="journal" id="cit61">
  <name>
   <surname>Costabile</surname>
   <given-names>G.</given-names>
  </name>; 
  <name>
   <surname>d’Angelo</surname>
   <given-names>I.</given-names>
  </name>; 
  <name>
   <surname>Rampioni</surname>
   <given-names>G.</given-names>
  </name>; 
  <name>
   <surname>Bondì</surname>
   <given-names>R.</given-names>
  </name>; 
  <name>
   <surname>Pompili</surname>
   <given-names>B.</given-names>
  </name>; 
  <name>
   <surname>Ascenzioni</surname>
   <given-names>F.</given-names>
  </name>; 
  <name>
   <surname>Mitidieri</surname>
   <given-names>E.</given-names>
  </name>; 
  <name>
   <surname>d’Emmanuele di Villa Bianca</surname>
   <given-names>R.</given-names>
  </name>; 
  <name>
   <surname>Sorrentino</surname>
   <given-names>R.</given-names>
  </name>; 
  <name>
   <surname>Miro</surname>
   <given-names>A.</given-names>
  </name>; 
  <name>
   <surname>Quaglia</surname>
   <given-names>F.</given-names>
  </name>; 
  <name>
   <surname>Imperi</surname>
   <given-names>F.</given-names>
  </name>; 
  <name>
   <surname>Leoni</surname>
   <given-names>L.</given-names>
  </name>; 
  <name>
   <surname>Ungaro</surname>
   <given-names>F.</given-names>
  </name> (
  <year>2015</year>) 
  <article-title>Toward repositioning niclosamide for antivirulence therapy of 
   <italic>Pseudomonas aeruginosa</italic> lung infections: Development of inhalable formulations through nanosuspension technology
  </article-title>. 
  <source>Mol. Pharmaceutics</source>
  <volume>12</volume>, 
  <fpage>2604</fpage>–
  <lpage>2617</lpage>. 
  <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.5b00098</pub-id>.
 </mixed-citation>
</ref>
